Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
CBM's Cash-to-Debt is ranked higher than
99% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. CBM: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CBM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.28 Max: No Debt
Current: No Debt
Equity-to-Asset 0.66
CBM's Equity-to-Asset is ranked lower than
51% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CBM: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
CBM' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.44 Max: 0.66
Current: 0.66
0.22
0.66
Interest Coverage 164.34
CBM's Interest Coverage is ranked lower than
71% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBM: 164.34 )
Ranked among companies with meaningful Interest Coverage only.
CBM' s Interest Coverage Range Over the Past 10 Years
Min: 4.34  Med: 24.06 Max: N/A
Current: 164.34
Piotroski F-Score: 8
Altman Z-Score: 7.80
Beneish M-Score: -2.48
WACC vs ROIC
22.16%
30.21%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 26.16
CBM's Operating Margin % is ranked higher than
90% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. CBM: 26.16 )
Ranked among companies with meaningful Operating Margin % only.
CBM' s Operating Margin % Range Over the Past 10 Years
Min: -2.77  Med: 12.14 Max: 26.16
Current: 26.16
-2.77
26.16
Net Margin % 16.65
CBM's Net Margin % is ranked higher than
86% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. CBM: 16.65 )
Ranked among companies with meaningful Net Margin % only.
CBM' s Net Margin % Range Over the Past 10 Years
Min: 3.18  Med: 10.67 Max: 82.87
Current: 16.65
3.18
82.87
ROE % 23.06
CBM's ROE % is ranked higher than
93% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. CBM: 23.06 )
Ranked among companies with meaningful ROE % only.
CBM' s ROE % Range Over the Past 10 Years
Min: 8.97  Med: 17.12 Max: 120.02
Current: 23.06
8.97
120.02
ROA % 14.83
CBM's ROA % is ranked higher than
94% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. CBM: 14.83 )
Ranked among companies with meaningful ROA % only.
CBM' s ROA % Range Over the Past 10 Years
Min: 2.22  Med: 8.84 Max: 42.71
Current: 14.83
2.22
42.71
ROC (Joel Greenblatt) % 38.99
CBM's ROC (Joel Greenblatt) % is ranked higher than
89% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. CBM: 38.99 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CBM' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1.19  Med: 16.08 Max: 38.99
Current: 38.99
-1.19
38.99
3-Year Revenue Growth Rate 13.10
CBM's 3-Year Revenue Growth Rate is ranked higher than
65% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. CBM: 13.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CBM' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -18.1  Med: 0.3 Max: 13.4
Current: 13.1
-18.1
13.4
3-Year EBITDA Growth Rate 25.80
CBM's 3-Year EBITDA Growth Rate is ranked higher than
76% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. CBM: 25.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CBM' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -27.2  Med: -0.5 Max: 33.1
Current: 25.8
-27.2
33.1
3-Year EPS without NRI Growth Rate 39.30
CBM's 3-Year EPS without NRI Growth Rate is ranked higher than
87% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. CBM: 39.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CBM' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -21.5  Med: 19.4 Max: 79.7
Current: 39.3
-21.5
79.7
GuruFocus has detected 1 Warning Sign with Cambrex Corp $CBM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CBM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CBM Guru Trades in Q1 2016

Third Avenue Management 76,681 sh (New)
Columbia Wanger 287,570 sh (New)
Paul Tudor Jones 7,400 sh (+23.33%)
Chuck Royce 203,298 sh (+0.89%)
Joel Greenblatt Sold Out
Jim Simons 162,300 sh (-49.15%)
» More
Q2 2016

CBM Guru Trades in Q2 2016

Steven Cohen 111,900 sh (New)
RS Investment Management 84,110 sh (New)
Columbia Wanger 314,909 sh (+9.51%)
Third Avenue Management 76,681 sh (unchged)
Paul Tudor Jones 7,164 sh (-3.19%)
Chuck Royce 170,598 sh (-16.08%)
Jim Simons 34,300 sh (-78.87%)
» More
Q3 2016

CBM Guru Trades in Q3 2016

Third Avenue Management 83,939 sh (+9.47%)
Steven Cohen 113,400 sh (+1.34%)
Jim Simons Sold Out
Paul Tudor Jones 6,734 sh (-6.00%)
Columbia Wanger 190,786 sh (-39.42%)
Chuck Royce 68,098 sh (-60.08%)
» More
Q4 2016

CBM Guru Trades in Q4 2016

Columbia Wanger 269,795 sh (+41.41%)
Paul Tudor Jones 8,182 sh (+21.50%)
Chuck Royce 81,598 sh (+19.82%)
Steven Cohen Sold Out
Third Avenue Management 83,585 sh (-0.42%)
» More
» Details

Insider Trades

Latest Guru Trades with CBM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2834
Compare:NAS:ARRY, NAS:SRPT, NAS:ONCE, NAS:LXRX, NAS:AGIO, NAS:HALO, NAS:NKTR, NAS:LGND, OTCPK:MPSYY, OTCPK:ABCZF, NAS:FPRX, NAS:SAGE, OTCPK:BVNRY, NAS:INVA, NYSE:EBS, NAS:ACOR, NAS:ALDR, OTCPK:PFSCF, NAS:CLVS, NAS:RGEN » details
Traded in other countries:XBX.Germany,
Cambrex Corp is a life sciences company. It provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics.

Cambrex Corp was incorporated as a Delaware corporation in 1981 and began business in December 1981. It is a life sciences company that provides products and services that accelerate and improve the development and commercialization of new and generic therapeutics. The Company supplies its products and services to innovator and generic pharmaceutical companies. The Company has four operating segments, which are manufacturing facilities that have been aggregated as one reportable segment. The Company participates in markets that serve the healthcare industry. Its customers include generic drug companies and companies that discover and commercialize new small molecule human therapeutics using organic chemistry. The Company uses its technical expertise in chemical processes to meet the needs of its customers for high quality products and services for specialized applications. The Company's business is comprised of the custom development and manufacture of pharmaceutical ingredients derived from organic chemistry. The products and services are supplied globally to innovator and generic drug companies. Its products include APIs, pharmaceutical intermediates and other fine chemicals. The Company's products and services are sold to a diverse group of several hundred customers, with one customer, Gilead Sciences, Inc. The manufacturing of pharmaceutical products is subject to extensive regulation by governmental authorities, including the FDA, the European Medicines Agency and comparable regulatory authorities in other countries.

Guru Investment Theses on Cambrex Corp

Third Avenue Comments on Cambrex Corp - May 27, 2016

Cambrex Corp. (NYSE:CBM) We took advantage of the February sell off in the market to acquire shares of Cambrex at around $38 per share, an attractive discount to our estimate of NAV. We see the combination of a strong balance sheet and a healthy revenue outlook as supportive for book value growth to continue, given the dynamics of Cambrex's business.


Cambrex is a well-financed specialty chemical company focused on life sciences; it develops and commercializes active pharmaceutical ingredients (APIs). Cambrex also produces Generic APIs, Controlled Substance APIs and is expanding into finished-dosage generic API manufacturing. Cambrex's API business is unique in that it manufactures the active ingredient in several leading pharmaceuticals and serves as a supplier to various drug companies. As such, it generates revenues from volumes sold and not price per finished pill. Cambrex's customers focus not only on product purity but also on quality, consistency and documentation of the manufacturing process ascompetitive attributes.


Several long-term drivers support revenue growth for Cambrex.



  1. Cambrex is a substantial beneficiary of the U.S. Federal Drug Administration's (FDA) significantly enhanced effort to ensure quality manufacturing processes. The company has benefitted as larger pharmaceutical companies have re-shored their API sourcing activities to "Western" Current Good Manufacturing Practice (CGMP) companies.

  2. Industry growth remains healthy, aided by the increasing number of small molecule drug developments and pending regulatory approvals in the U.S. and Europe.

  3. Pharmaceutical companies are continuing to reduce their own manufacturing activities and thus turning to outsourcing firms, such as Cambrex, to focus on new drug development.

Cambrex is in the midst of a capacity expansion in Charles City, Iowa that should drive significant revenue growth as this capacity is completed and filled for the next few years.



From Chip Rewey's second quarter 2016 Third Avenue Small-Cap Value Fund letter.



Check out Martin Whitman,Third Avenue Management latest stock trades

Top Ranked Articles about Cambrex Corp

Third Avenue Comments on Cambrex Corp Guru stock highlight
Cambrex Corp. (NYSE:CBM) We took advantage of the February sell off in the market to acquire shares of Cambrex at around $38 per share, an attractive discount to our estimate of NAV. We see the combination of a strong balance sheet and a healthy revenue outlook as supportive for book value growth to continue, given the dynamics of Cambrex's business.

Read more...

Ratios

vs
industry
vs
history
PE Ratio 22.63
CBM's PE Ratio is ranked higher than
62% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. CBM: 22.63 )
Ranked among companies with meaningful PE Ratio only.
CBM' s PE Ratio Range Over the Past 10 Years
Min: 1.05  Med: 15.85 Max: 59.25
Current: 22.63
1.05
59.25
Forward PE Ratio 18.32
CBM's Forward PE Ratio is ranked higher than
60% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. CBM: 18.32 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 21.12
CBM's PE Ratio without NRI is ranked higher than
63% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. CBM: 21.12 )
Ranked among companies with meaningful PE Ratio without NRI only.
CBM' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.27  Med: 16.46 Max: 94.8
Current: 21.12
5.27
94.8
Price-to-Owner-Earnings 20.48
CBM's Price-to-Owner-Earnings is ranked higher than
61% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. CBM: 20.48 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CBM' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 1.28  Med: 19.93 Max: 364.38
Current: 20.48
1.28
364.38
PB Ratio 4.44
CBM's PB Ratio is ranked lower than
57% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. CBM: 4.44 )
Ranked among companies with meaningful PB Ratio only.
CBM' s PB Ratio Range Over the Past 10 Years
Min: 0.61  Med: 2.24 Max: 5.9
Current: 4.44
0.61
5.9
PS Ratio 3.72
CBM's PS Ratio is ranked higher than
78% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. CBM: 3.72 )
Ranked among companies with meaningful PS Ratio only.
CBM' s PS Ratio Range Over the Past 10 Years
Min: 0.18  Med: 1.36 Max: 10.86
Current: 3.72
0.18
10.86
Price-to-Free-Cash-Flow 24.96
CBM's Price-to-Free-Cash-Flow is ranked lower than
54% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. CBM: 24.96 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CBM' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.86  Med: 16.2 Max: 128.39
Current: 24.96
4.86
128.39
Price-to-Operating-Cash-Flow 14.85
CBM's Price-to-Operating-Cash-Flow is ranked higher than
66% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. CBM: 14.85 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CBM' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 2.91  Med: 10.86 Max: 63.52
Current: 14.85
2.91
63.52
EV-to-EBIT 13.73
CBM's EV-to-EBIT is ranked higher than
60% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. CBM: 13.73 )
Ranked among companies with meaningful EV-to-EBIT only.
CBM' s EV-to-EBIT Range Over the Past 10 Years
Min: -118.8  Med: 11.9 Max: 306.6
Current: 13.73
-118.8
306.6
EV-to-EBITDA 11.55
CBM's EV-to-EBITDA is ranked higher than
61% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. CBM: 11.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
CBM' s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.8  Med: 8.3 Max: 35.9
Current: 11.55
-0.8
35.9
PEG Ratio 0.90
CBM's PEG Ratio is ranked higher than
76% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. CBM: 0.90 )
Ranked among companies with meaningful PEG Ratio only.
CBM' s PEG Ratio Range Over the Past 10 Years
Min: 0.48  Med: 1.26 Max: 7.94
Current: 0.9
0.48
7.94
Shiller PE Ratio 28.85
CBM's Shiller PE Ratio is ranked higher than
76% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. CBM: 28.85 )
Ranked among companies with meaningful Shiller PE Ratio only.
CBM' s Shiller PE Ratio Range Over the Past 10 Years
Min: 2.83  Med: 28.07 Max: 326.5
Current: 28.85
2.83
326.5
Current Ratio 3.38
CBM's Current Ratio is ranked lower than
57% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CBM: 3.38 )
Ranked among companies with meaningful Current Ratio only.
CBM' s Current Ratio Range Over the Past 10 Years
Min: 1.72  Med: 2.55 Max: 3.48
Current: 3.38
1.72
3.48
Quick Ratio 2.09
CBM's Quick Ratio is ranked lower than
69% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. CBM: 2.09 )
Ranked among companies with meaningful Quick Ratio only.
CBM' s Quick Ratio Range Over the Past 10 Years
Min: 0.88  Med: 1.5 Max: 2.09
Current: 2.09
0.88
2.09
Days Inventory 165.34
CBM's Days Inventory is ranked lower than
62% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. CBM: 165.34 )
Ranked among companies with meaningful Days Inventory only.
CBM' s Days Inventory Range Over the Past 10 Years
Min: 124.14  Med: 131.78 Max: 165.34
Current: 165.34
124.14
165.34
Days Sales Outstanding 82.29
CBM's Days Sales Outstanding is ranked lower than
64% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. CBM: 82.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.84  Med: 63.9 Max: 82.29
Current: 82.29
49.84
82.29
Days Payable 54.64
CBM's Days Payable is ranked lower than
52% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 57.94 vs. CBM: 54.64 )
Ranked among companies with meaningful Days Payable only.
CBM' s Days Payable Range Over the Past 10 Years
Min: 37.86  Med: 51.72 Max: 63.55
Current: 54.64
37.86
63.55

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.00
CBM's 3-Year Average Share Buyback Ratio is ranked higher than
84% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. CBM: -2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CBM' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -4.1  Med: -1.6 Max: -0.1
Current: -2
-4.1
-0.1

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 15.57
CBM's Price-to-Net-Current-Asset-Value is ranked lower than
81% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. CBM: 15.57 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CBM' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 14.96  Med: 19.12 Max: 23.2
Current: 15.57
14.96
23.2
Price-to-Tangible-Book 5.16
CBM's Price-to-Tangible-Book is ranked lower than
56% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. CBM: 5.16 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CBM' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.33  Med: 4.17 Max: 12.46
Current: 5.16
2.33
12.46
Price-to-Intrinsic-Value-Projected-FCF 2.52
CBM's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
59% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. CBM: 2.52 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
CBM' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.02  Med: 2.4 Max: 9.84
Current: 2.52
1.02
9.84
Price-to-Median-PS-Value 2.76
CBM's Price-to-Median-PS-Value is ranked lower than
88% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. CBM: 2.76 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CBM' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.4  Med: 1.3 Max: 2.76
Current: 2.76
0.4
2.76
Price-to-Peter-Lynch-Fair-Value 0.99
CBM's Price-to-Peter-Lynch-Fair-Value is ranked higher than
67% of the 72 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. CBM: 0.99 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
CBM' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.57  Med: 1.33 Max: 3.09
Current: 0.99
0.57
3.09
Price-to-Graham-Number 2.20
CBM's Price-to-Graham-Number is ranked higher than
55% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 2.38 vs. CBM: 2.20 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CBM' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.82  Med: 1.65 Max: 4.28
Current: 2.2
0.82
4.28
Earnings Yield (Greenblatt) % 7.24
CBM's Earnings Yield (Greenblatt) % is ranked higher than
90% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. CBM: 7.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CBM' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 8.1 Max: 209.9
Current: 7.24
0.3
209.9
Forward Rate of Return (Yacktman) % 22.90
CBM's Forward Rate of Return (Yacktman) % is ranked higher than
61% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. CBM: 22.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
CBM' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -35.3  Med: 7.5 Max: 23
Current: 22.9
-35.3
23

More Statistics

Revenue (TTM) (Mil) $490.6
EPS (TTM) $ 2.47
Beta2.65
Short Percentage of Float3.30%
52-Week Range $37.01 - 62.50
Shares Outstanding (Mil)32.35

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 544 596
EPS ($) 3.05 3.40
EPS without NRI ($) 3.05 3.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)
» More Articles for CBM

Headlines

Articles On GuruFocus.com
Third Avenue Comments on Cambrex Corp May 27 2016 
Chip Rewey's Third Avenue Small-Cap Value Fund 2nd Quarter Commentary May 27 2016 
Royce Smaller-Companies Growth Fund Annual Letter Mar 19 2016 
Royce Smaller-Companies Growth Fund Shareholder Letter Sep 20 2015 
Cambrex Corp. Reports Operating Results (10-Q) Aug 04 2010 
Cambrex Corp. Reports Operating Results (10-Q) May 05 2010 
Does Cambrex Corporation Have Earnings Persistence? Apr 28 2010 
Cambrex Corp. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
Cleantech Building Materials: Auditor Resignation and Appointment Feb 21 2017
Cambrex Corp. breached its 50 day moving average in a Bullish Manner : CBM-US : February 17, 2017 Feb 17 2017
Cambrex to Present at the 2017 RBC Capital Markets Global Healthcare Conference Feb 15 2017
ETFs with exposure to Cambrex Corp. : February 14, 2017 Feb 14 2017
CAMBREX CORP Financials Feb 08 2017
Cambrex Corp. :CBM-US: Earnings Analysis: 2016 By the Numbers : February 8, 2017 Feb 08 2017
Cambrex Corp. :CBM-US: Earnings Analysis: Q4, 2016 By the Numbers : February 7, 2017 Feb 07 2017
Cambrex Corp.: Leads amongst peers with strong fundamentals Feb 06 2017
Edited Transcript of CBM earnings conference call or presentation 3-Feb-17 1:30pm GMT Feb 03 2017
Q4 2016 Cambrex Corp Earnings Release - Before Market Open Feb 03 2017
Cambrex posts 4Q profit Feb 03 2017
Cambrex posts 4Q profit Feb 03 2017
CAMBREX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 03 2017
Cambrex Reports Fourth Quarter and Full Year 2016 Financial Results Feb 03 2017
Cambrex to Announce Fourth Quarter and Full Year 2016 Financial Results on February 3, 2017 Feb 01 2017
Cleantech Building Materials: LOAN CONVERSION AND ISSUE OF NEW SHARES Jan 27 2017
Cambrex Corp. – Value Analysis (NYSE:CBM) : January 25, 2017 Jan 25 2017
Cambrex Corp. breached its 50 day moving average in a Bearish Manner : CBM-US : January 24, 2017 Jan 24 2017
Merck KGaA Expands Distribution Deal with Roche (revised) Jan 17 2017
Momenta (MNTA) to Receive $50M Under CSL Collaboration Jan 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)